featured
Lazertinib vs Gefitinib Tyrosine Kinase Inhibitors for Treatment-Naïve EGFR-Mutated Advanced NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
J Thorac Oncol 2023 Oct 01;18(10)1351-1361, T Reungwetwattana, BC Cho, KH Lee, YK Pang, CH Fong, JH Kang, YG Lee, CS Lim, P Danchaivijitr, YN Lim, Y Lee, SH How, S Geater, SS Lee, YJ Min, JH Kim, JS Lee, GW Lee, RA Soo, SY Lee, S Choi, MJ AhnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.